Monthly Archives: June 2017

Filly Flair Now Offers a Wide Variety of Women’s Clothing Including Boutique Dresses, Lace Dresses and Not Rated Boots

The Company’s Online Boutique, FillyFlair.com, is User-Friendly and Lets Customers Shop for Stylish Women’s Clothing 24/7

BALTIC, SD / ACCESSWIRE / June 29, 2017 / Laura Benson, owner of Filly Flair, is pleased to announce that her online and retail store now offers an even wider selection of women’s clothing including holiday dresses, boutique dresses, Not Rated boots and many other fashionable items.

To learn more about Filly Flair and check out the wide variety of boutique tops, bottoms, shoes, bridesmaid’s dresses and much more, people are welcome to visit the easy-to-navigate website at any time, or come into the retail shop in Sioux Falls, South Dakota.

As Benson noted, Filly Flair had a rather humble beginning. She started her business back in 2010 out of the basement of her home. At the time, Benson was a single gal who had one key goal in mind: to help every woman feel beautiful in her own skin.

Fast forward seven years later, and Benson is now a wife and mother to two kids, and her company includes the retail location along with a huge warehouse in Baltic, South Dakota. Benson now has a team of 20 employees, and over the years they have shipped hundreds of thousands of orders to customers all over the country.

Now, with the addition of more women’s clothing items like lace dresses and more, Benson hopes that more women than ever will find exactly what they are looking for at Filly Flair.

“As a wife and mother, I understand the need to be comfortable and have clothes that you can wear while chasing kids around, but still wanting to look stylish,” she said, adding that Filly Flair offers clothing for women of all ages.

“It does not matter if you are a college girl, mother, where you live, or what you do for a living. All women deserve to feel amazing during every season of life.”

From the All In Black Lace Dress for $38 that is popular with customers, to the Not Rated A Little Edge Boots for $72, Benson is proud to offer women clothing that will fit a variety of bodies and budgets.

“We thrive on helping women see that they are just as beautiful on the outside as they are on the inside,” she said.

About Filly Flair:

Filly Flair provides affordable, quality fashion wear for women. From dresses, skirts, and jeans, to shoes, boots, accessories and more, shoppers can visit the online boutique at any time of the day or night. For more information, please visit https://www.fillyflair.com/.

Contact:

Laura Benson
Support@FillyFlair.com
(855) 777-3455

SOURCE: Filly Flair

ReleaseID: 467131

Featured Company News – Hill-Rom to Divest Volker Business; Unifies its Business Strategy to Front Line Care Business

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hill-Rom Holdings, Inc. (NYSE: HRC), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HRC. The Company announced on June 27, 2017, that it has entered into an agreement to sell its Volker business, to an affiliate of CoBe Capital. Under terms of the transaction, the CoBe affiliate will acquire multiple Volker assets and assume the operations and employees at the subsidiary’s current location in Witten, North-Westphalia, Germany. The financial terms of the agreement were not disclosed. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HRC. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=HRC.

The Announcement

This announcement from Hill-Rom comes in the light of Company’s constant efforts to optimize its portfolio and direct investment. Hill-Rom plans to focus on resources, and key, strategic growth platforms to deliver exceptional, long-term value to its shareholders.

Volker was initially established in 1912, in Witten, Germany, where it focused on delivering active patient-centered healthcare. Volker is one of Germany’s premiere producers of hospital and long-term care beds, and Hill-Rom acquired it in 2012. The acquisition further expanded Hill-Rom’s offering and portfolio to healthcare facilities.

In FY16, Volker’s net revenues stood at $40 million, subject to the execution of the agreement, Hill-Rom expects to record an after-tax special charge of about $30 million, principally for the non-cash write down of assets and transaction-related costs.

The Welch Allyn Campus Expansion

Prior to the announcement, on May 05, 2017, the Company reported that it had begun a facility expansion that would add about 100,000 square feet to its Welch Allyn Campus. This agreement came in light of the announcement in September 2016, when the Company committed to bringing more than 100 new jobs to Central New York where Welch Allyn had maintained a significant presence for more than 100 years. Welch Allyn is the largest component of Hill-Rom’s Front Line Care business, where Hill-Rom additionally plans to accommodate new positions, including R&D and engineering roles. Owing to the Trump’s policy of creating new jobs in the US itself, this announcement fuelled the Company’s growth strategy in the domestic market.

Company Growth Prospects

Hill-Rom is a global medical technology leader, which operates through more than 10,000 employees worldwide. The Company partners with healthcare providers in more than 100 nations, across different care settings. On May 18, 2017, the Company announced the launch of the new Hill-Rom 900 Accella bed system for higher acuity patients in intensive and acute care settings. The new bed system was made available in only selected markets outside the US.

Later, on May 22, 2017, the Company announced the launch of the new Hill-Rom® Envella™ Air Fluidized Therapy Bed, which allows the highest quality wound care for patients with advanced wounds. The Company observed different aspects, including increased bed depth, adjustable air flow, and sensing technologies, to advanced weight-based pressure distribution. Considering the extremely prevalent nature of pressure injuries, with one in 10 patients having it and one in 20 patients experiencing a facility-acquired pressure injury during their stay in the hospital, the demand for such a bed turns mandatory for efficient patient comfort and care.

The Company announced on May 26, 2017, a dividend of $0.18 per share payable on June 30, 2017, to shareholders of record as of the close of business on June 16, 2017.

Last Close Stock Review

Hill-Rom’s share price finished yesterday’s trading session at $79.97, rising 1.34%. A total volume of 315.18 thousand shares have exchanged hands. The Company’s stock price skyrocketed 12.55% in the last three months, 39.88% in the past six months, and 66.40% in the previous twelve months. Additionally, the stock soared 42.45% since the start of the year. Shares of the Company have a PE ratio of 34.48 and have a dividend yield of 0.90%. The stock currently has a market cap of $5.27 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467082

Earnings Review and Free Research Report: Science Applications International’s EPS Soared 52%

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Science Applications International Corp. (NYSE: SAIC), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=SAIC, following the Company’s disclosure of its first quarter fiscal 2017 earnings results on June 13, 2017. The information technology Company surpassed earnings expectations. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SAIC. With the links below you can directly download the report of your stock of interest free of charge at: http://protraderdaily.com/optin/?symbol=SAIC.

Earnings Reviewed

For the first three months ended May 05, 2017, SAIC’s sales decreased 9.22% to $1.10 billion from $1.21 billion in Q1 2016. The decrease was due to one additional week in the prior year’s same quarter and the increased costs and investment on its platform integration programs. The Company’s revenue numbers came in below analysts’ expectations of $1.12 billion.

During Q1 2017, SAIC’s gross profit margin was 8.7%, down 0.9% from Q1 2016. The operating margin for the reported quarter was 5.7% compared to 5.4% in Q1 2016 primarily due to platform integration program impacts, offset by the reduction in estimated lease exit costs.

SAIC’s net income for Q1 2017 was $49 million up by 48.5% compared to $33 million in Q1 2016 due to lower income tax expense as a result of the adoption of the new accounting standard for excess tax benefits from stock-based compensation. The diluted earnings per share for the reported quarter were $1.08 compared to $0.71 for the prior year’s corresponding quarter. Earnings came in ahead of Wall Street’s expectations of $1.04 per share.

For the reported quarter, the Company’s adjusted EBITDA was $73 million, or 6.6% of revenue, compared to 7.1% for Q1 2016. EBITDA was impacted by higher net unfavorable contract estimates of $11 million, which included $9 million on its platform integration programs.

New Business Awards

SAIC’s net bookings for Q1 2017 were approximately $1.3 billion, which reflects a book-to-bill ratio of approximately 1.2. SAIC’s estimated backlog of signed business orders at the end of the quarter was approximately $8.2 billion of which $1.8 billion was funded.

Balance Sheet

As on May 05, 2017 SAIC’s cash and cash equivalents were $207 million above its average operating cash balance target of $150 million. The Company had total debt of $1.01 billion, equating to a bank EBITDA leverage ratio of less than 3x for the reported quarter.

For the reported quarter, operating cash flow increased to $88 million a 151.4% increase from $35 million in Q1 2016. The increase was primarily due to payments for an extra week of payroll in the prior year’s same quarter, excess tax benefits for stock based compensation in the current year’s same quarter, and the prior year’s working capital investments in Marine Corps platform integration and IT services programs.

During Q1 2017, SAIC deployed $61 million of capital, consisting of $38 million in plan share repurchases under SAIC’s previously announced share repurchase program, $14 million in cash dividends, and $9 million for a voluntary debt prepayment.

Subsequent to quarter-end, SAIC’s Board of Directors declared a cash dividend of $0.31 per share of the Company’s common stock payable on July 28, 2017, to stockholders of record on July 14, 2017.

Outlook

SAIC expects full year profitability, as measured by EBITDA margin, to be 10 basis points lower than the prior year due to the impact of the platform integration programs.

For fiscal 2018 year, the Company expects $240 million of free cash flow nearly $20 million more than the previous estimate of $220 million. It expects to pay dividends of $55 million, make total debt payments of approximately $25 million, with the remainder of cash in excess of $150 million available for further share repurchase and strategic M&A.

Stock Performance

At the close of trading session on Wednesday, June 28, 2017, Science Applications’ stock price rose 2.11% to end the day at $70.64. A total volume of 211.65 thousand shares were exchanged during the session. The Company’s share price has surged 27.95% in the past twelve months. Shares of the Company have a PE ratio of 19.67 and have a dividend yield of 1.76%. The stock currently has a market cap of $3.08 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467089

Earnings Review and Free Research Report: Tidewater Reported Better than Expected Results

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Tidewater Inc. (NYSE: TDW), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=TDW, following the Company’s release of its fourth quarter Results

fiscal 2017 financial results on June 12, 2017. The offshore fleet services provider’s net loss narrowed. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TDW. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=TDW

Earnings Reviewed

For the period ended March 31, 2017, Tidewater reported revenues of $160.7 million compared to revenues of $184.2 million for the prior year’s same quarter. The Company’s revenue numbers surpassed analysts’ expectations of $118.75 million. For FY17, Tidewater reported revenues of $601.6 million compared to revenues of $979.1 million in FY16.

Tidewater reported a net loss for the period ended March 31, 2017, of $94.9 million, or $2.01 per common share. Included in the net loss for the quarter ended March 31, 2017, were $64.9 million after-tax, or $1.38 per share in non-cash asset impairment charges, $16.8 million after-tax, or $0.36 per share of general and administrative expenses related to debt renegotiations, and $31.3 million after-tax and consideration of noncontrolling interests, or $0.67 per share of revenue related to the early termination of a long-term vessel charter contract. For the prior fiscal year’s fourth quarter ended March 31, 2016, Tidewater’s net loss was $81.8 million, or $1.74 per common share. On an adjusted basis, the Company reported a loss of $0.40 per share, surpassing Wall Street’s expectations for a loss of $1.29 per share.

For FY17, Tidewater reported a net loss of $660.1 million, or $14.02 per common share, compared to net loss of $160.2 million, or $3.41 per common share.

Cash Matters

During fiscal years ended March 31, 2017 and 2016, Tidewater generated net cash from operating activities of $29.8 million and $253.4 million, respectively, and generated net cash in investing activities of $14.9 million and used net cash in investing activities of $135.0 million, respectively.

Reorganization and Chapter 11 Proceedings

On May 17, 2017, Tidewater and certain of its subsidiaries filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware, seeking approval of a prepackaged plan of restructuring.

On May 19, 2017, the Bankruptcy Court set a combined hearing to consider approval of the Debtors’ disclosure statement and confirmation of the Prepackaged Plan for June 28, 2017. Tidewater stated that if the Prepackaged Plan is approved by the Bankruptcy Court within the time frame the Company expects, the Prepackaged Plan will likely become effective in July 2017, at which point or shortly thereafter Debtors would emerge from bankruptcy.

Tidewater stated that given the pendency of the Bankruptcy Cases, it will not be hosting an earnings conference call to discuss fiscal 2017 financial results. However, the Company expects to resume holding quarterly earnings conference calls following its emergence from bankruptcy.

Stock Performance

On Wednesday, June 28, 2017, the stock closed the trading session at $0.73, declining 3.95% from its previous closing price of $0.76. A total volume of 635.22 thousand shares have exchanged hands. At Wednesday’s closing price, the stock’s net capitalization stands at $34.37 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467084

Earnings Review and Free Research Report: Dominion Diamond’s Q1 Top-line rose 18% on Positive Diamond Market

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Dominion Diamond Corp. (NYSE: DDC), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=DDC, following the Company’s reporting of its financial results for the first quarter fiscal 2018 (Q1 FY18) on June 12, 2017. The Yellowknife, Canada-based Company reported 18% y-o-y growth in its quarterly sales. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on DDC. With the links below you can directly download the report of your stock of interest free of charge at: http://protraderdaily.com/optin/?symbol=DDC.

Earnings Reviewed

During the quarter ended on April 30, 2017, Dominion Diamond reported sales of $210.98 million compared to $178.26 million recorded at the end of Q1 FY17. The Company’s sales growth of approximately $33 million from the prior year is primarily attributed to a positive diamond market along with an auction of approximately $21 million of high value fancy colored diamonds.

The diamond mining Company reported a net loss of $7.84 million, or $0.09 loss per diluted share, in Q1 FY18 compared to $5.30 million, or $0.01 per diluted share, in Q1 FY17. The Company’s net loss includes a foreign currency exchange impact on income tax expense of $13.6 million, or $0.16 per share, and restructuring costs of $2.3 million, or $0.02 per share, relating to the relocation of the corporate head office.

Operational Metrics

For the reported quarter, Dominion Diamond’s cost of sales was $210.98 million compared to $178.26 million in Q1 FY17. The Company reported gross profit of $30.77 million in Q1 FY18 against gross loss of $18.82 million in the year ago same quarter. During Q1 FY18, Dominion Diamond’s selling, general, and administrative expenses were $8.28 million versus $8.04 million in the prior year’s comparable quarter. The Company’s operating profit for Q1 FY18 came in at $20.22 million compared to operating loss of $26.85 million in Q1 FY17. Furthermore, the Company’s adjusted EBITDA increased to $97.0 million, or 46% of sales, in Q1 FY18 from $54.3 million, or 30% of sales, in last year’s comparable quarter.

Mine-Performance

Dominion Diamond’s Ekati Mine reported a y-o-y growth in sales during Q1 FY18 to $137.7 million from $105.1 million in Q1 FY17. The mine sold 1.83 million carats of diamonds at $75 per carat in Q1 FY18 compared to 1.55 million carats at $68 per carat in the previous year’s same quarter. The mine’s adjusted EBITDA surged to $64.3 million, or 47% of mine sales, in Q1 FY18 from $25.9 million, or 25% of mine sales, in the previous year’s corresponding quarter.

Diavik Mine’s sales stood at $73.3 million in Q1 FY18 compared to $73.1 million in the previous year’s same quarter. Diamond sales fell to 0.50 million carats in Q1 FY18 from 1.06 million carats in the year ago same quarter. However, average sales price surged to $147 per carat in Q1 FY17 from $69 per carat in the last year’s comparable quarter. Furthermore, the mine reported adjusted EBITDA of $40.3 million, or 55% of mine sales, in Q1 FY18 compared to $34.5 million, or 47% of mine sales, in the prior year’s corresponding quarter.

Cash Flow & Balance Sheet

During first three months of FY18, cash provided by operating activities was $56.68 million compared to $17.96 million in the prior year’s same period. At the close of books on April 30, 2017, Dominion Diamond had $131.17 million in cash and cash equivalents compared to $136.17 million at the close of books on January 31, 2017.

Share Repurchase

During Q1 FY18, the Company continued the share repurchase as per previously announced share repurchase plan. Since summer 2016 till May 2017, the company has returned approximately C$61 million to shareholders through repurchases and the cancellation of approximately 4.8 million shares.

Stock Performance

Dominion Diamond’s share price finished yesterday’s trading session at $12.79, slightly up 0.95%. A total volume of 329.47 thousand shares have exchanged hands. The Company’s stock price skyrocketed 0.47% in the last three months, 38.72% in the past six months, and 48.03% in the previous twelve months. Additionally, the stock soared 32.13% since the start of the year. Shares of the Company have a dividend yield of 3.13% and currently have a market cap of $1.03 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467091

Platinum Rapid Funding Group Featured on Money Inc.

In the Article, Ali Mayar Answered a Number of Questions about his Company, Platinum Rapid Funding Group, Including How it has Grown, his Most Memorable Moment and Strategies he has Used to Help the Company be Successful

LOS ANGELES, CA / ACCESSWIRE / June 29, 2017 / Ali Mayar, founder and CEO of Platinum Rapid Funding Group, is pleased to announce that he and his company were recently featured in an article in Money Inc.

To read the in-depth story in its entirety and learn more about Platinum Rapid Funding Group, please check out http://moneyinc.com/key-insights-leadership-management-interview-platinum-rapid-funding-group/.

In the article, Mayar described how his company has grown since he first started it in 2012. As he told the writer, his goal in launching Platinum Rapid Funding Group was to help as many small and medium-sized merchants as possible to access the funds they needed for projects that will help their companies to move forward.

“Since our inception, we have used a combination of key resources like proprietary data, manpower, available technologies, and more, to grow our company,” Mayar said.

“Because of the diligence we have exercised on our part, and the commitment to our unique business model, we have been able to exceed our goals and have helped countless companies over the years.”

While there have been a number of memorable moments since starting Platinum Rapid Funding Group, Mayar said getting positive feedback from clients who have benefited from his company’s services are always especially important to him and his team.

“We genuinely want to help in a way that is effective and impactful and whenever we can do that, it becomes a special moment for us,” he said.

As for unique strategies that have helped Platinum Rapid Funding Group really rise above the rest, Mayar said he has found a perfect combination of a few key approaches. For example, his desire to create an advantageous position in the cash advancement arena has led to him to create a unique business model that involves leveraging manpower, technological resources, and proprietary data and information.

“In addition to employing a uniquely business model, and staying true to our fundamentals, we have been able to forge key alliances that have paved the way for healthy financial growth and expansion,” Mayar said in the article.

About Platinum Rapid Funding Group:

Platinum Rapid Funding Group was established in 2012 and is a merchant cash advance provider working with small and medium sized business nationwide. Learn more about Platinum Rapid Funding Group by visiting their website, https://platinumrapidfunding.com/.

Contact:

Dean Rhodes
admin@rocketfactor.com
(949) 555-2861

SOURCE: Platinum Rapid Funding Group

ReleaseID: 467129

Alzheimer’s Disease : Exceptional Level of First-in-Class Innovation and Diverse Range of Therapies in Development

Alzheimer’s Disease report provides Management and Treatment of Alzheimer’s Disease, Pipeline by Stage of Development and Molecule Type, First-in-Class Target Profiles and Strategic Consolidations

June 29, 2017 /MarketersMedia/

Alzheimer’s disease and Associated Indications, Exceptional Level of First-in-Class Innovation within Alzheimer’s disease, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression ocuses on Alzheimer’s disease alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden. Alzheimer’s disease pipeline is large, with 646 products in active development. In addition, the level of first-in-class innovation within the pipeline is exceptionally high – 65.3% of products with a disclosed molecular target have been identified as first-in-class. In comparison, the Pipeline for Alzheimer’s disease associated indications is smaller and less innovative. There are 272 products in development across the four associated indications, and only 27.7% of those with a disclosed molecular target are first in class. However, the diversity of first-in-class targets identified is greater than that of the Alzheimer’s disease pipeline.

Request Sample Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=1039051 .

The deals landscape for AD and AD-associated indications has been fairly active over the past decade. The aggregate deal value for licensing deals reached $13.0 billion, while the aggregate deal value for co-development deals totaled $10.7 billion. Small molecule products and those targeting GPCRs have dominated the landscape in terms of both deal frequency and aggregate value.

The prevalence of Alzheimer’s disease is escalating rapidly, largely as a result of aging populations. This will amplify the already substantial societal and economic costs of the disease over the coming decades. However, despite this large market opportunity, there are no disease-modifying therapies currently available that are capable of halting, reversing or effectively modifying the course of disease progression. Treatment options are extremely limited and can only temporarily slow the worsening of symptoms (Alzheimer’s Association, 2017 a; Yiannopoulou and Papageorgiou, 2013). Additionally, many aspects of the disease pathophysiology remain incompletely understood, and these knowledge gaps underlie the poor treatment options currently available to AD patients, and the failed attempts to improve on these therapies in clinical trials.

Get Discount on Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1039051 .

Moreover, this report allows you to:
• Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
• Identify leading products and key unmet needs within the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Direct Purchase This Report @ http://www.reportsnreports.com/purchase.aspx?name=1039051 .

Table of Contents:
• Executive Summary
• The Case for Innovation
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Signaling Network, Disease Causation and Innovation Alignment
• First-in-Class Target Profiles
• Strategic Consolidations

About Us:
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets.

Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsnreports.com
Organization: ReportsnReports
Address: Pune
Phone: +1-888-391-5441

Source URL: http://marketersmedia.com/alzheimers-disease-exceptional-level-of-first-in-class-innovation-and-diverse-range-of-therapies-in-development/212163

For more information, please visit http://www.reportsnreports.com/reports/1039051-frontier-pharma-alzheimers-disease-and-associated-indications-exceptional-level-of-first-in-class-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression.html

Source: MarketersMedia

Release ID: 212163

Long Island Same Day Dental Implants Denture Repair And Fabrication Lab Launched

The Franklin Square, Long Island dental office of Island Dental Associates has launched a fully staffed, on-site dental lab which is attached to their existing full-service dental office giving patients the benefits of true same day service for denture repairs and dental implant fabrication.

Franklin Square, United States – June 29, 2017 /PressCable/

The renowned Island Dental Associates has announced it has launched an on-site dental lab that allows patients to receive dental implants, relines, denture repairs, dentures and other tooth replacement and dental restoration needs with same day service.

More information is available at: https://www.facebook.com/IslandDentalAssociates/

Island Dental Associates is an acclaimed and popular Long Island, New York-based dental office, with over 20 years of experience providing the best dental care to its patients along with healthy, beautiful smiles that they can be very proud of with its convenient, affordable and premier range of implant, denture, cosmetic and general dentistry services.

The launch of a new on-site dental lab has been announced by the popular dental office which enables patients to conveniently receive crowns, dental implants, relines, denture repairs, dentures or any tooth replacement or dental restoration need serviced conveniently within the same day. This allows the patient’s dentist to be able to better supervise the work that is being performed to ensure proper fitting and higher quality.

Island Dental Associates’ new state-of-the-art dental lab is connected to its office and is conveniently located at 639 Hempstead Turnpike in Franklin Square, NY. The dental lab is fully staffed with experienced technicians who are equipped with the highest quality materials and latest technology. They work directly with the patient’s dentist in order to provide the most natural feel, size, shape, color and fit on all dental restorations.

Appointments and free consultations with Island Dental Associates are available along with more information on its same-day dental restoration services, on-site dental lab, or leading range of general dentistry solutions in addition to smile galleries, numerous patient testimonials and details on the renowned and expert team of dentists lead by Dr. Eric Weinstein and Dr. Vikas Mittle and Dr. Eric Weinstein can be obtained by calling 516-565-6565.

According to the team at Island Dental Associates, this is Long Island’s first on-site dental lab. It offers their customers tremendous benefits by bringing all of their dental services under the same roof, meaning that same day services can be performed, including relines, denture repairs and dental restorations, and have them fabricated under the strict control of the dentists to ensure the most natural look and best fit, and all times.

Contact Info:
Name: Dr. Eric Weinstein
Organization: Island Dental Associates
Address: 639 Hempstead Turnpike, Franklin Square, NY 11010, United States
Phone: +1-516-565-6565

For more information, please visit https://www.youtube.com/watch?v=B697-YYoccg

Source: PressCable

Release ID: 212104

Dr. Karl Jawhari On How To Determine Bulging vs Herniated Discs

Learn what a jelly donut has to do with a herniated disc.

Dallas, TX – June 29, 2017 /MarketersMedia/

Dr. Karl Jawhari, D.C., started the Dallas Spine and Disc Center to be a medically-integrated clinic specializing in chronic back pain. He has dedicated his career to developing groundbreaking treatments for bulging and herniated spinal discs. Often described as being similar to a jelly donut – consisting of a firm outer layer of tough cartilage surrounding a softer layer composed of cartilage fibers suspended in a mucoprotein gel – the purpose of intervertebral discs is to cushion and act as a shock absorber between adjacent vertebrae, as well as to serve as connecting ligaments holding spinal vertebrae together. While tough enough to typically absorb a lifetime of shock and impact, the effects of poor posture, spinal injury, repetitive strain and the normal wear and tear of aging can lead to a bulging disc or a herniated disc and associated pain.

“Intervertebral discs are an amazing bit of engineering,” says Dr. Karl Jawhari. “The twenty-three discs help keep the spine in alignment and prevent the vertebra from contacting each other, while also staying soft and pliable. But it is not a flawless system, and bulging discs or herniated discs may occur.”

A bulging disc is medically described as “contained,” meaning there is no tear or rupture is present within the outer layer of the disc, although it is pushing outward and into the spinal canal. The degree of pain depends on whether the disc impinges a nerve root. It may not be painful at all, or it may produce mild symptoms ranging from numbness, tingling and weakness up to severe pain. Coughing, sneezing, sitting, driving and bending forward can make the pain worse due to additional pressure put on the nerve by these various activities.

Herniated discs are the second condition that commonly account for chronic back pains and are described as “non-contained,” meaning a tear or rupture is present. They often begin as a bulging disc, until long-term extended pressure on the outer wall leads to a herniation. The pain from a herniated disc is frequently much greater than with a bulging disc, as it is caused by both compression of the nerve, in combination with painful inflammation of the nerve root caused by the gel-like nucleus pulposus leaking into the spinal canal.

Dr. Karl Jawhari, D.C., is the founder of Dallas Spine and Disc, an innovative healthcare center with a focus on back pain. He is a nationally recognized speaker for the Health Awareness Foundation, a non-profit organization that promotes health and wellness in local companies by educating employees and creating a healthier environment through workshops. Dr. Jawhari has consulted with over 120 doctors in the U.S. on the application of non-surgical healing techniques such as New Life Laser, lumbar decompression, litecure laser and cervical decompression. He and his talented staff have treated hundreds of patients who previously had little expectation of relief from chronic pain.

Dr. Karl Jawhari, D.C. – Founder of Dallas Spine and Disc Center: http://www.DrKarlJawhariNews.com

Dr. Karl Jawhari – LinkedIn: https://www.linkedin.com/in/dr-karl-jawhari-1b84b516

Karl Jawhari (@DrKarlJawhari) – Twitter: https://twitter.com/drkarljawhari

Contact Info:
Name: Dr. Karl Jawhari
Email: contact@drkarljawharinews.com
Organization: DrKarlJawhariNews.com

Source URL: http://marketersmedia.com/dr-karl-jawhari-on-how-to-determine-bulging-vs-herniated-discs/212473

For more information, please visit http://drkarljawharinews.com

Source: MarketersMedia

Release ID: 212473

Breast Cancer Treatment Market Epidemiology Forecast to 2025

Breast Cancer Treatment Market Epidemiology Forecast to 2025 report provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China).

June 29, 2017 /MarketersMedia/

Breast Cancer (HER2+, HER2-) Epidemiology Forecast to 2025 provides an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year Breast Cancer epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.

Get Discount on Breast Cancer (HER2+, HER2-) Epidemiology Forecast to 2025 99 Pages Report@ http://www.reportsnreports.com/contacts/discount.aspx?name=798545 .

Breast Cancer Epidemiology Forecast to 2025 report provides that Epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60–69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015.
According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent (IARC, 2014). Prolonged exposure to endogenous and exogenous sex hormones; gene mutations; a family history of breast cancer; overweightness and obesity; physical inactivity; a sedentary lifestyle; high alcohol consumption; early age at menarche (younger than 12 years); late age at menopause (older than 55 years); and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density, are all risk factors for breast cancer (ACS, 2011).

You can Request Sample Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=798545 .

The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN. For initial stage at diagnosis throughout the forecast period, 37.82% of diagnosed incident cases of invasive breast cancer were in stage I, 43.19% were in stage II, 14.59% were in stage III, and 4.40% were in stage IV, in the 8MM.

List of Tables:
• Table 1: Risk Factors and Comorbidities for Breast Cancer 12
• Table 2: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%) 17
• Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer 21
• Table 4: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status 22
• Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer 23
• Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status 24
• Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer 25
• Table 8: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis 26
• Table 9: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis 27
• Table 10: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis 28
• Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status 29
• Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis 30
• Table 13: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression 31
• Table 14: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer 53
• Table 15: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 55
• Table 16: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 57
• Table 17: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 59
• Table 18: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N (Row %), 2015 61
• Table 19: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 64
• Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, N, 2015 66
• Table 21: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 68

Purchase This EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 Report at http://www.reportsnreports.com/purchase.aspx?name=798545 .

About Us:
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsnreports.com
Organization: ReportsnReports
Address: Pune
Phone: +1-888-391-5441

Source URL: http://marketersmedia.com/breast-cancer-treatment-market-epidemiology-forecast-to-2025/212141

For more information, please visit http://www.reportsnreports.com/reports/798545-epicast-report-breast-cancer-her2-her2-epidemiology-forecast-to-2025.html

Source: MarketersMedia

Release ID: 212141